US20140255486A1 - Coated Tablet Formulation and Method - Google Patents
Coated Tablet Formulation and Method Download PDFInfo
- Publication number
- US20140255486A1 US20140255486A1 US14/284,840 US201414284840A US2014255486A1 US 20140255486 A1 US20140255486 A1 US 20140255486A1 US 201414284840 A US201414284840 A US 201414284840A US 2014255486 A1 US2014255486 A1 US 2014255486A1
- Authority
- US
- United States
- Prior art keywords
- coating layer
- coated
- tablet
- inner seal
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- MJSPZDMZMZEFNH-TVHXTYDWSA-N [C-]#[N+][C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2 Chemical compound [C-]#[N+][C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2 MJSPZDMZMZEFNH-TVHXTYDWSA-N 0.000 description 8
- JPVVXJXFVUWKGT-GZNCTARVSA-N C=C(F)C1([C@H](N)C(=O)N2C3C[C@H]3C[C@H]2C)CCCC1.C[C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C1(CO)CCC1.C[C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C1(CO)CCCC1.N#C[C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CCC(CC1)C2.[C-]#[N+][C@@H]1C[C@@H]2CC2C1C(=C)C(N)C1(CO)CCCCC1.[C-]#[N+][C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CC3CC(CC(C3)C1)C2.[C-]#[N+][C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CC3CC(CC(F)(C3)C1)C2.[C-]#[N+][C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2 Chemical compound C=C(F)C1([C@H](N)C(=O)N2C3C[C@H]3C[C@H]2C)CCCC1.C[C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C1(CO)CCC1.C[C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C1(CO)CCCC1.N#C[C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CCC(CC1)C2.[C-]#[N+][C@@H]1C[C@@H]2CC2C1C(=C)C(N)C1(CO)CCCCC1.[C-]#[N+][C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CC3CC(CC(C3)C1)C2.[C-]#[N+][C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CC3CC(CC(F)(C3)C1)C2.[C-]#[N+][C@@H]1C[C@@H]2CC2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2 JPVVXJXFVUWKGT-GZNCTARVSA-N 0.000 description 1
- COFHUYQXCURNQW-UHFFFAOYSA-N N=C1NC(C23CC4CC(CC(O)(C4)C2)C3)C(=O)N2C1CC1CC12.[H]N([H])C(C(=O)N1C(C#N)CC2CC21)C12CC3CC(CC(O)(C3)C1)C2 Chemical compound N=C1NC(C23CC4CC(CC(O)(C4)C2)C3)C(=O)N2C1CC1CC12.[H]N([H])C(C(=O)N1C(C#N)CC2CC21)C12CC3CC(CC(O)(C3)C1)C2 COFHUYQXCURNQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a coated tablet formulation which includes a tablet core coated with a medicament such as a DPP4-inhibitor, such as saxagliptin, and to a method for preparing such coated tablet formulation.
- a medicament such as a DPP4-inhibitor, such as saxagliptin
- DPP4-inhibitor or saxaglipitin is an orally active reversible dipeptidyl peptidase-4 (DPP4) inhibitor, which is a therapeutic agent for treatment of Type-2 diabetes mellitus which is disclosed in U.S. Pat. No. 6,395,767.
- insulinotropic hormone GLP-1 After a meal intake, insulinotropic hormone GLP-1 is released which in turn induces insulin release from the pancreas.
- Some of the GLP-1 is inactivated by the DPP4 present in plasma and intestinal capillary endothelium. Therefore, if the DPP4 is inhibited, more GLP-1 will be available to activate insulin release from the pancreas.
- the advantage of this mechanism of insulin release is that insulin is secreted only in response to a meal. Therefore, problems of hypoglycemia associated with other diabetes drugs will be less likely with a DPP4 inhibitor.
- the above DPP4 inhibitor is a labile compound which is prone to an intra-molecular cyclization as shown below.
- cyclic amidine mainly cis-cyclic amidine (CA)
- CA cis-cyclic amidine
- This cyclization reaction can occur both in solid state and solution state.
- the rate of intra-molecular cyclization is accelerated when formulations are subject to commonly used processing activities such as wet granulation, roller compaction, or tabletting.
- most commonly used excipients when mixed with this compound, can accelerate the rate of cyclization.
- the level of cis-cyclic amidine increases when the drug to excipient ratio increases posing more challenges for low strength dosage forms. Given these properties of the molecule, manufacture of a conventional tablet dosage form for the DPP4-inhibitor, which is a preferred dosage form, is not a viable option.
- capsule formulations containing a dry mix of the DPP4-inhibitor and commonly used excipients are manufactured at a small scale and used for clinical studies.
- the scale up of capsule formulations containing the DPP4-inhibitor will also be problematic since it will involve milling to control the particle size of the DPP4-inhibitor so that capsules of lower strengths are manufactured without content unifomity problems.
- the pharmaceutically acceptable salt can be the hydrochloride salt or the trifluoroacetic acid salt.
- DPP4 inhibitors including those set out above may be formulated as tablets, capsules, granules or powders.
- a coated tablet which may include a medicament which is subject to intra-molecular cyclization, but is surprisingly stable under normal storage conditions, that is at 30° C. and 60% relative humidity.
- the coated tablet of the invention includes a tablet core (also referred to as a “core”, “tablet core”, “placebo”, “placebo core tablet”, “tablet core composition” or “core composition”) and
- a coating layer coated on the core which coating layer is an inner seal coat formed of at least one coating polymer
- a second coating layer disposed over the inner seal coat, formed of a medicament and at least one coating polymer which preferably is the same coating polymer in the inner seal coat;
- an outer protective coating layer disposed over the second coating layer, formed of at least one coating polymer, which preferably is the same coating polymer in the second coating layer and inner seal coat, but need not necessarily include the same amounts of such polymer.
- the medicament will preferably be the DPP4-inhibitor of the structure
- the coated tablet of the invention will include a tablet core which is formed of one or more bulking agents or fillers, optionally one or more binders, optionally one or more disintegrants, and optionally one or more tableting lubricants,
- an inner seal coating layer which includes at least one coating polymer which preferably is a polyvinyl alcohol (PVA) based polymer;
- the above coating layers are applied to the tablet core preferably by spray coating on to the tablet core.
- an outer protective or third coating layer will be coated over the second coating layer (containing the medicament) and will function as a protective layer.
- the third or protective coating layer may preferably include similar components as in the second coating layer except that it will not include a medicament, but may optionally include one or more colorants, and may not necessarily include the same amounts of such components.
- a fourth layer (which includes similar components as in the third layer) containing colorants and a coating polymer can also be applied to differentiate tablets of various strengths.
- the first, second, third and fourth coating layers may be formed of the same or different coating polymers.
- coated tablets of the invention exhibit superior chemical stability as compared to traditional tablets manufactured using conventional dry granulation or wet granulation techniques.
- the coating approach will also facilitate preparation of a combination formulation of a problematic medicament with another drug by using the other drug tablet as a starting tablet (instead of the tablet core or placebo mentioned above) and applying the inner seal coating and the second coating containing the problematic medicament and coating polymer, and optionally but preferably, the outer protective coating over the other drug tablet.
- coated tablets of the invention may be prepared preferably using perforated pan coaters. Fluid bed coating and spray coating may be used as well.
- a method for preparing the coated tablet of the invention which method includes the steps of
- the inner seal coating layer formulation, the second coating layer formulation and the outer protective coating layer(s) formulation(s) each will be applied as a suspension of the coating polymer in a coating solvent.
- the third and fourth outer protective coating layers need not include a medicament (although it may, if desired), and may be formed of the other components of the first coating layer and/or second coating layer.
- the second coating layer may be formed of the components of the first coating layer and/or third/and or fourth coating layer, but not necessarily the same amounts of such components.
- coating suspensions which include coating polymer in water are prepared.
- Other coating solvents which may be employed include ethanol, methanol, and isopropyl alcohol, with water being preferred.
- Tablets which are placebos (contain no medicament) and form tablet cores are coated with the inner seal coating suspension and are dried.
- the second coating layer suspension containing medicament and coating polymer is applied over the so-coated tablets which are then dried.
- a coating suspension is prepared as in the case of the inner seal coating suspension but without medicament.
- the coating suspension will then be coated onto the previously coated tablets as described for the inner seal coating and second coating to form a protective coating layer thereon.
- coated tablets of the invention are useful in the treatment of mammals such as humans, dogs and cats for Type II diabetes.
- the tablet core or placebo employed in the coated tablet of the invention will include conventional pharmaceutical excipients to enable formation of a pharmaceutically acceptable solid tablet core.
- the tablet core may be in the form of a tablet, bead, beadlet, or pill, all of the above being collectively referred to as a tablet core.
- the coated tablet of the invention will contain medicament, such as the above
- DPP4-inhibitor in an amount within the range from about 0.1 to about 70% by weight and preferably from about 1 to about 50% by weight of the tablet core.
- the tablet core employed in the coated tablet of the invention will preferably contain
- the bulking agent or filler is present in an amount within the range from about 1 to about 95% by weight, preferably from about 10 to about 85% by weight;
- the binder is present in an amount within the range from about 0 to about 20% by weight, preferably from about 1 to about 10% by weight;
- the disintegrant is present in an amount within the range from about 0 to about 20% by weight, and preferably from about 0.25 to about 10% by weight;
- the lubricant is present in an amount within the range from about 0 to about 5% by weight, preferably from about 0.2 to about 2% by weight, all of the above % by weight being based on the weight of the tablet core.
- the bulking agents are microcrystalline cellulose and lactose monohydrate
- the disintegrant is croscarmellose sodium
- the lubricant is magnesium stearate.
- the tablet cores present in the coated tablets of this invention can be prepared by a variety of processes and order of addition of excipients.
- the utility of these formulations is not limited to a specific dosage form or manufacturing process.
- Tablet cores may be manufactured by wet granulation, dry granulation, direct blending or any other pharmaceutically acceptable process.
- a preferred method for preparing the tablet cores employed in the coated tablets of the invention which includes the steps of blending the one or more excipients such as bulking agent, optionally binder and optionally disintegrant.
- a lubricant will be preferably added to the blend to facilitate tablet formation.
- the bulking agents or fillers will be present in the tablet core compositions of the invention in an amount within the range from about 1 to about 95% by weight and preferably from about 10 to about 85% by weight of the core composition.
- Examples of bulking agents or fillers suitable for use herein include, but are not limited to, cellulose derivatives such as microcrystalline cellulose or wood cellulose, lactose, sucrose, starch, pregelatinized starch, dextrose, mannitol, fructose, xylitol, sorbitol, corn starch, modified corn starch, inorganic salts such as calcium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, dextrin/dextrates, maltodextrin, compressible sugars, and other known bulking agents or fillers, and/or mixtures of two or more thereof, preferably microcrystalline cellulose.
- the binder will be optionally present in the pharmaceutical compositions of the invention in an amount within the range from about 0 to about 20% weight, preferably from about 1 to about 10% by weight of the core composition.
- binders suitable for use herein include, but are not limited to, hydroxypropyl cellulose, corn starch, pregelatinized starch, modified corn starch, polyvinyl pyrrolidone (PVP) (molecular weight ranging from about 5,000 to about 1,000,000, preferably about 40,000), hydroxypropyl methylcellulose (HPMC), lactose, gum acacia, ethyl cellulose, cellulose acetate, as well as a wax binder such as carnauba wax, paraffin, spermaceti, polyethylenes or microcrystalline wax, as well as other conventional binding agent and/or mixtures by two or more thereof, preferably hydroxypropyl cellulose.
- PVP polyvinyl pyrrolidone
- HPMC hydroxypropyl methylcellulose
- the disintegrant will be optionally present in the pharmaceutical composition of the invention in an amount within the range from about 0 to about 20% by weight, preferably from about 0.25 to about 10% by weight of the core composition.
- disintegrants suitable for use herein include, but are not limited to, croscarmellose sodium, crospovidone, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose or other known disintegrant, preferably croscarmellose sodium.
- the lubricant will be optimally present in the pharmaceutical composition of the invention in an amount within the range from about 0.1 to about 5% by weight, preferably from about 0.2 to about 2% by weight of the core composition.
- tableting lubricants suitable for use herein include, but are not limited to, magnesium stearate, zinc stearate, calcium stearate, talc, carnauba wax, stearic acid, palmitic acid, sodium stearyl fumarate or hydrogenated vegetable oils and fats, or other known tableting lubricants, and/or mixtures of two or more thereof, preferably magnesium stearate.
- the inner seal coating layer formulation (also referred to as the first coating layer) will include up to 95% of polymer based on the weight of the inner seal coating layer, and may be prepared as described hereinbefore.
- the formulation will contain at least one coating layer polymer and a coating solvent as described above, which preferably is water, which is used for processing and removed by drying.
- the coating layer polymer may be hydroxypropyl methylcellulose, polyvinyl alcohol (PVA), ethyl cellulose, methacrylic polymers or hydroxypropyl cellulose, preferably PVA.
- the coating layer may also optionally include a plasticizer such as triacetin, diethyl phthalate, tributyl sebacate or polyethylene glycol (PEG), preferably PEG; and an anti-adherent or glidant such as talc, fumed silica or magnesium stearate, opacifying agent such as titanium dioxide.
- PEG polyethylene glycol
- the coating layer may also include iron oxide based colorants.
- the coating material is commercially available under the trade name Opadry® HP or Opadry® II white.
- the second coating layer formulation will preferably be similar in composition to the first coating layer formulation although it will include medicament, preferably the DPP4-inhibitor in an amount within the range from about 0.5 to about 70%, preferably from about 30 to about 50% by weight, based on the weight of the second coating layer.
- the third outer protective coating layer will preferably be similar in composition to the first coating layer.
- the fourth coating layer where present will preferably be similar in composition to the third outer protective coating layer and will include colorant as desired, such as within the range from about 0.5 to about 5.0% by weight, based on the weight of the fourth coating layer.
- the inner seal coating layer will preferably be formed of coating layer polymer in an amount within the range from about 10 to about 95%, preferably from about 20 to about 90% by weight of the inner seal coating layer, optionally plasticizer in an amount within the range from about 10 to about 30%, preferably from about 15 to about 20% by weight of the coating layer, and anti-adherent or glidant in an amount within the range for about 15 to about 30%, preferably from about 10 to about 15% by weight of the inner seal coating layer.
- the second coating layer will be preferably formed of coating layer polymer in an amount within the range from about 30 to about 99.5%, preferably from about 40 to about 60% by weight of the second coating layer and medicament in an amount within the range from about 0.25% to about 70%, preferably from about 20 to about 50% by weight of the second coating layer.
- the coating layer polymer in the second coating layer will be at least about 5 mg with a 200 mg tablet core, and the medicament will be at least about 0.5 mg.
- the third outer protective coating layer will preferably be of similar composition to the first coating layer.
- the inner seal coating layer will be present in an amount within the range from about 1 to about 5%, preferably from about 1 to about 3% by weight of the finished coated tablet; the second coating layer (containing medicament) will be present in an amount within the range from about 0.25 to about 70%, preferably from about 1 to about 50% by weight of the finished coated tablet, depending on potency; and the third outer protective coating layer and fourth layer where present will each be present in an amount within the range from about 1 to about 10%, preferably from about 1 to about 5% by weight of the finished coated tablet.
- Preferred coated tablet formulations in accordance with the invention are set out below.
- the 500 g of tablet cores were prepared as follows.
- Lactose monohydrate, croscarmellose sodium, and microcrystalline cellulose were blended in a planetary mixer.
- the blend was then lubricated by blending with pre-screened magnesium stearate using a Turbula mixer.
- the lubricated blend was compressed using a single station press or using a rotary press into 200 mg placebo tablets.
- the inner seal coating suspension was prepared as follows.
- 0.1 N HCl (about 226.7 g) in a metal container was continuously stirred with a lightening mixer.
- 40 g Opadry® HP powder was quickly added into the vortex. After the powder addition was completed, mixing was continued at a low speed until a uniform mixture was visually evident. pH of the resulting suspension was measured and pH was adjusted to 2 using concentrated HCl or NaOH.
- Glatt coater was set up according to the following parameters
- the tablet cores were preheated in a coating pan for about 10 to 15 minutes. 30 heated tablets were weighed. Drying of the tablets was continued until the moisture was driven out of the tablet and tablet weight became constant. The final weight of 30 tablets was designed as A.
- the 30 tablets were coated with the inner seal coating suspension as prepared above employing the Glatt coater.
- the 30 tablets were weighed every 10 minutes (and the weight recorded) until the tablet weight reached the targeted weight (Equation 1).
- the coated tablets were dried by heating until the tablet weight became constant.
- the final weight of the so- coated tablets was designated as B.
- the middle drug-containing coating layer suspension was prepared as follows.
- the seal coated tablet cores prepared above were coated with the coating suspension containing the DPP4-inhibitor prepared above employing the Glatt coater.
- the 30 seal coated tablets were weighed, initially every 30 minutes, then every 15 minutes and the weight recorded until the targeted weight was reached (Equation 2).
- the so-coated tablets were dried by heating until the tablet weight became constant.
- the final weight of 30 tablets was designated as C.
- the amount of drug coated onto the tablets was determined using HPLC, fiber optic probe, or NIR or other suitable means. Coating was stopped when the targeted amount of drug was deposited.
- the so-coated tablets were transferred to a suitable container.
- the tablets of the invention so-prepared had superior stability to conventional tablet formulations (wherein the drug was in the core) and capsule formulations.
- the above 2.5 mg potency coated tablets of the invention were stored at various storage conditions up to and including 41 weeks and stability data related to presence of the degradant cyclic amidine (mainly cis-cyclic amidine (Cis-CA)) were collected.
- cyclic amidine mainly cis-cyclic amidine (Cis-CA)
- Table 1 set out below, no cis-CA was detected at 25° C./60% RH storage condition.
- the cis-CA levels were 0.22% and 0.32% at 30° C./60% RH and 40° C./75% RH storage conditions, respectively. These levels are significantly lower than those observed in the 5 mg and 20 mg potency capsule formulations shown in Table 2.
Abstract
A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin
or its HCl salt,
which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
Description
- This application is a continuation of U.S. patent application Ser. No. 14/150,331, filed Jan. 8, 2014, which is a continuation of U.S. patent application Ser. No. 13/094,379, filed Apr. 26, 2011, issued as U.S. Pat. No. 8,628,799 B2, which is a divisional application of U.S. patent application Ser. No. 11/137,068, filed May 25, 2005, issued as U.S. Patent No. 7,951,400 B2, which claims a benefit of priority from U.S. Provisional Application No. 60/575,319, filed May 28, 2004, the entire disclosure of each of which is herein incorporated by reference.
- The present invention relates to a coated tablet formulation which includes a tablet core coated with a medicament such as a DPP4-inhibitor, such as saxagliptin, and to a method for preparing such coated tablet formulation.
- The compound of the structure
- or its HCl salt,
(hereinafter the above DPP4-inhibitor or saxaglipitin) is an orally active reversible dipeptidyl peptidase-4 (DPP4) inhibitor, which is a therapeutic agent for treatment of Type-2 diabetes mellitus which is disclosed in U.S. Pat. No. 6,395,767. - After a meal intake, insulinotropic hormone GLP-1 is released which in turn induces insulin release from the pancreas. Some of the GLP-1 is inactivated by the DPP4 present in plasma and intestinal capillary endothelium. Therefore, if the DPP4 is inhibited, more GLP-1 will be available to activate insulin release from the pancreas. The advantage of this mechanism of insulin release is that insulin is secreted only in response to a meal. Therefore, problems of hypoglycemia associated with other diabetes drugs will be less likely with a DPP4 inhibitor.
- The above DPP4 inhibitor is a labile compound which is prone to an intra-molecular cyclization as shown below.
- The resultant degradant, cyclic amidine (mainly cis-cyclic amidine (CA)), is not therapeutically active and therefore, its formation is not desirable. This cyclization reaction can occur both in solid state and solution state. The rate of intra-molecular cyclization is accelerated when formulations are subject to commonly used processing activities such as wet granulation, roller compaction, or tabletting. In addition, most commonly used excipients, when mixed with this compound, can accelerate the rate of cyclization. Moreover, the level of cis-cyclic amidine increases when the drug to excipient ratio increases posing more challenges for low strength dosage forms. Given these properties of the molecule, manufacture of a conventional tablet dosage form for the DPP4-inhibitor, which is a preferred dosage form, is not a viable option.
- Currently, capsule formulations containing a dry mix of the DPP4-inhibitor and commonly used excipients are manufactured at a small scale and used for clinical studies. The scale up of capsule formulations containing the DPP4-inhibitor will also be problematic since it will involve milling to control the particle size of the DPP4-inhibitor so that capsules of lower strengths are manufactured without content unifomity problems.
- Additionally, most of the therapeutic agents as a single entity or as a combination product for diabetes treatments are available in a tablet dosage form. Since a tablet dosage form using traditional manufacturing process is not feasible for the DPP4-inhibitor, its manufacturing with other therapeutic agents, as a combination tablet will be even more problematic.
- Thus, it is seen that there is clearly a need for stable pharmaceutical formulations containing medicaments which are subject to intra-molecular cyclization which results in formation of degradants such as cyclic amidines which are not therapeutically active.
- U.S. Pat. No. 6,395,767 to Robl et al. (hereinafter Robl et al.) discloses cyclopropyl-fused pyrrolidine-based dipeptidyl peptidase IV inhibitors (DPP4 inhibitors) which include compounds having the structure
- or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt can be the hydrochloride salt or the trifluoroacetic acid salt.
- Robl et al. discloses that the DPP4 inhibitors including those set out above may be formulated as tablets, capsules, granules or powders.
- In accordance with the present invention a coated tablet is provided which may include a medicament which is subject to intra-molecular cyclization, but is surprisingly stable under normal storage conditions, that is at 30° C. and 60% relative humidity.
- The coated tablet of the invention includes a tablet core (also referred to as a “core”, “tablet core”, “placebo”, “placebo core tablet”, “tablet core composition” or “core composition”) and
- a) a coating layer coated on the core, which coating layer is an inner seal coat formed of at least one coating polymer;
- b) a second coating layer, disposed over the inner seal coat, formed of a medicament and at least one coating polymer which preferably is the same coating polymer in the inner seal coat; and optionally
- c) an outer protective coating layer, disposed over the second coating layer, formed of at least one coating polymer, which preferably is the same coating polymer in the second coating layer and inner seal coat, but need not necessarily include the same amounts of such polymer.
- The medicament will preferably be the DPP4-inhibitor of the structure
- or a pharmaceutically acceptable salt thereof, such as the HCl salt, also referred to as Compound A.
- In a preferred embodiment, the coated tablet of the invention will include a tablet core which is formed of one or more bulking agents or fillers, optionally one or more binders, optionally one or more disintegrants, and optionally one or more tableting lubricants,
- a) an inner seal coating layer which includes at least one coating polymer which preferably is a polyvinyl alcohol (PVA) based polymer;
- b) a second coating layer disposed over the seal coating layer a) which includes at least one medicament and at least one coating polymer which is preferably a PVA based polymer, and preferably the same as the coating polymer of the inner seal coating layer.
- The above coating layers are applied to the tablet core preferably by spray coating on to the tablet core.
- In a more preferred embodiment of the invention, an outer protective or third coating layer will be coated over the second coating layer (containing the medicament) and will function as a protective layer. The third or protective coating layer may preferably include similar components as in the second coating layer except that it will not include a medicament, but may optionally include one or more colorants, and may not necessarily include the same amounts of such components. Optionally, a fourth layer (which includes similar components as in the third layer) containing colorants and a coating polymer can also be applied to differentiate tablets of various strengths. The first, second, third and fourth coating layers may be formed of the same or different coating polymers.
- It has been found that the coated tablets of the invention exhibit superior chemical stability as compared to traditional tablets manufactured using conventional dry granulation or wet granulation techniques.
- The coating approach will also facilitate preparation of a combination formulation of a problematic medicament with another drug by using the other drug tablet as a starting tablet (instead of the tablet core or placebo mentioned above) and applying the inner seal coating and the second coating containing the problematic medicament and coating polymer, and optionally but preferably, the outer protective coating over the other drug tablet.
- The coated tablets of the invention may be prepared preferably using perforated pan coaters. Fluid bed coating and spray coating may be used as well.
- In addition, in accordance with the present invention, a method is provided for preparing the coated tablet of the invention, which method includes the steps of
- a) providing a tablet core;
- b) coating the tablet with an inner seal coating layer formulation which includes at least one coating polymer;
- c) drying the coated tablet to form an inner seal coating thereon;
- d) coating the so-coated tablet with a second coating layer formulation which includes medicament and at least one coating polymer;
- e) drying the so-coated tablet to form a second coating layer (containing medicament) thereon;
- f) optionally, but preferably, coating the so-coated tablet with a third outer protective coating layer formulation which includes at least one coating polymer; and
- g) optionally, coating the so-coated tablet with a fourth outer protective coating layer which includes at least one coating polymer and colorant, and
- h) drying the so-coated tablet to form the coated tablet of the invention.
- In a preferred embodiment of the method of the invention the inner seal coating layer formulation, the second coating layer formulation and the outer protective coating layer(s) formulation(s) each will be applied as a suspension of the coating polymer in a coating solvent.
- The third and fourth outer protective coating layers need not include a medicament (although it may, if desired), and may be formed of the other components of the first coating layer and/or second coating layer. The second coating layer may be formed of the components of the first coating layer and/or third/and or fourth coating layer, but not necessarily the same amounts of such components.
- In preparing the coated tablet of the invention, coating suspensions which include coating polymer in water are prepared. Other coating solvents which may be employed include ethanol, methanol, and isopropyl alcohol, with water being preferred. Tablets which are placebos (contain no medicament) and form tablet cores are coated with the inner seal coating suspension and are dried. The second coating layer suspension containing medicament and coating polymer is applied over the so-coated tablets which are then dried.
- Where the coated tablet of the invention is to include an outer protective layer, a coating suspension is prepared as in the case of the inner seal coating suspension but without medicament. The coating suspension will then be coated onto the previously coated tablets as described for the inner seal coating and second coating to form a protective coating layer thereon.
- The coated tablets of the invention are useful in the treatment of mammals such as humans, dogs and cats for Type II diabetes.
- The tablet core or placebo employed in the coated tablet of the invention will include conventional pharmaceutical excipients to enable formation of a pharmaceutically acceptable solid tablet core. The tablet core may be in the form of a tablet, bead, beadlet, or pill, all of the above being collectively referred to as a tablet core.
- The coated tablet of the invention will contain medicament, such as the above
- DPP4-inhibitor, saxaglipitin, in an amount within the range from about 0.1 to about 70% by weight and preferably from about 1 to about 50% by weight of the tablet core.
- The tablet core employed in the coated tablet of the invention will preferably contain
- a) at least one bulking agent or filler;
- b) optionally at least one binder;
- c) optionally at least one disintegrant; and
- d) preferably but optionally at least one lubricant.
- wherein
- a) the bulking agent or filler is present in an amount within the range from about 1 to about 95% by weight, preferably from about 10 to about 85% by weight;
- b) the binder is present in an amount within the range from about 0 to about 20% by weight, preferably from about 1 to about 10% by weight;
- c) the disintegrant is present in an amount within the range from about 0 to about 20% by weight, and preferably from about 0.25 to about 10% by weight; and
- d) the lubricant is present in an amount within the range from about 0 to about 5% by weight, preferably from about 0.2 to about 2% by weight, all of the above % by weight being based on the weight of the tablet core.
- It is preferred that the bulking agents are microcrystalline cellulose and lactose monohydrate;
- the disintegrant is croscarmellose sodium; and
- the lubricant is magnesium stearate.
- The tablet cores present in the coated tablets of this invention can be prepared by a variety of processes and order of addition of excipients. The utility of these formulations is not limited to a specific dosage form or manufacturing process. Tablet cores may be manufactured by wet granulation, dry granulation, direct blending or any other pharmaceutically acceptable process.
- In accordance with the present invention, a preferred method is provided for preparing the tablet cores employed in the coated tablets of the invention which includes the steps of blending the one or more excipients such as bulking agent, optionally binder and optionally disintegrant. A lubricant will be preferably added to the blend to facilitate tablet formation.
- The bulking agents or fillers will be present in the tablet core compositions of the invention in an amount within the range from about 1 to about 95% by weight and preferably from about 10 to about 85% by weight of the core composition. Examples of bulking agents or fillers suitable for use herein include, but are not limited to, cellulose derivatives such as microcrystalline cellulose or wood cellulose, lactose, sucrose, starch, pregelatinized starch, dextrose, mannitol, fructose, xylitol, sorbitol, corn starch, modified corn starch, inorganic salts such as calcium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, dextrin/dextrates, maltodextrin, compressible sugars, and other known bulking agents or fillers, and/or mixtures of two or more thereof, preferably microcrystalline cellulose.
- The binder will be optionally present in the pharmaceutical compositions of the invention in an amount within the range from about 0 to about 20% weight, preferably from about 1 to about 10% by weight of the core composition. Examples of binders suitable for use herein include, but are not limited to, hydroxypropyl cellulose, corn starch, pregelatinized starch, modified corn starch, polyvinyl pyrrolidone (PVP) (molecular weight ranging from about 5,000 to about 1,000,000, preferably about 40,000), hydroxypropyl methylcellulose (HPMC), lactose, gum acacia, ethyl cellulose, cellulose acetate, as well as a wax binder such as carnauba wax, paraffin, spermaceti, polyethylenes or microcrystalline wax, as well as other conventional binding agent and/or mixtures by two or more thereof, preferably hydroxypropyl cellulose.
- The disintegrant will be optionally present in the pharmaceutical composition of the invention in an amount within the range from about 0 to about 20% by weight, preferably from about 0.25 to about 10% by weight of the core composition.
- Examples of disintegrants suitable for use herein include, but are not limited to, croscarmellose sodium, crospovidone, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose or other known disintegrant, preferably croscarmellose sodium.
- The lubricant will be optimally present in the pharmaceutical composition of the invention in an amount within the range from about 0.1 to about 5% by weight, preferably from about 0.2 to about 2% by weight of the core composition. Examples of tableting lubricants suitable for use herein include, but are not limited to, magnesium stearate, zinc stearate, calcium stearate, talc, carnauba wax, stearic acid, palmitic acid, sodium stearyl fumarate or hydrogenated vegetable oils and fats, or other known tableting lubricants, and/or mixtures of two or more thereof, preferably magnesium stearate.
- The inner seal coating layer formulation (also referred to as the first coating layer) will include up to 95% of polymer based on the weight of the inner seal coating layer, and may be prepared as described hereinbefore. The formulation will contain at least one coating layer polymer and a coating solvent as described above, which preferably is water, which is used for processing and removed by drying. The coating layer polymer may be hydroxypropyl methylcellulose, polyvinyl alcohol (PVA), ethyl cellulose, methacrylic polymers or hydroxypropyl cellulose, preferably PVA. The coating layer may also optionally include a plasticizer such as triacetin, diethyl phthalate, tributyl sebacate or polyethylene glycol (PEG), preferably PEG; and an anti-adherent or glidant such as talc, fumed silica or magnesium stearate, opacifying agent such as titanium dioxide. The coating layer may also include iron oxide based colorants. The coating material is commercially available under the trade name Opadry® HP or Opadry® II white.
- The second coating layer formulation will preferably be similar in composition to the first coating layer formulation although it will include medicament, preferably the DPP4-inhibitor in an amount within the range from about 0.5 to about 70%, preferably from about 30 to about 50% by weight, based on the weight of the second coating layer.
- The third outer protective coating layer will preferably be similar in composition to the first coating layer.
- The fourth coating layer where present will preferably be similar in composition to the third outer protective coating layer and will include colorant as desired, such as within the range from about 0.5 to about 5.0% by weight, based on the weight of the fourth coating layer.
- The inner seal coating layer will preferably be formed of coating layer polymer in an amount within the range from about 10 to about 95%, preferably from about 20 to about 90% by weight of the inner seal coating layer, optionally plasticizer in an amount within the range from about 10 to about 30%, preferably from about 15 to about 20% by weight of the coating layer, and anti-adherent or glidant in an amount within the range for about 15 to about 30%, preferably from about 10 to about 15% by weight of the inner seal coating layer.
- The second coating layer will be preferably formed of coating layer polymer in an amount within the range from about 30 to about 99.5%, preferably from about 40 to about 60% by weight of the second coating layer and medicament in an amount within the range from about 0.25% to about 70%, preferably from about 20 to about 50% by weight of the second coating layer.
- The coating layer polymer in the second coating layer will be at least about 5 mg with a 200 mg tablet core, and the medicament will be at least about 0.5 mg.
- The third outer protective coating layer will preferably be of similar composition to the first coating layer.
- The inner seal coating layer will be present in an amount within the range from about 1 to about 5%, preferably from about 1 to about 3% by weight of the finished coated tablet; the second coating layer (containing medicament) will be present in an amount within the range from about 0.25 to about 70%, preferably from about 1 to about 50% by weight of the finished coated tablet, depending on potency; and the third outer protective coating layer and fourth layer where present will each be present in an amount within the range from about 1 to about 10%, preferably from about 1 to about 5% by weight of the finished coated tablet.
- Preferred coated tablet formulations in accordance with the invention are set out below.
-
Possible Range Preferred Range %/mg by weight of %/mg by weight of 200 mg placebo core 200 mg placebo core Material tablet tablet Tablet Placebo Bulking Agent 2 to 95%/4 to 190 mg 10 to 85%/20 to 170 mg Lactose 0 to 95%/0 to 190 mg 20 to 75%/40 to 150 mg Microcrystalline 0 to 95%/0 to 190 mg 20 to 75%/40 to 150 mg cellulose Disintegrant 0 to 20%/0 to 40 mg 0.25 to 10%/0.5 to 20 mg Croscarmellose 0 to 20%/0 to 40 mg 2 to 10%/4 to 20 mg sodium Lubricant 0.1 to 5%/0.2 to 10 mg 0.2 to 2%/0.4 to 4 mg Magnesium Stearate 0.1 to 5%/0.2 to 10 mg 0.2 to 2%/0.4 to 4 mg First Inner Seal Coating Layer Coating polymer, and 0.5 to 50%/1 to 100 1 to 3%/2 to 6 mg optional plasticizer mg and glidants Second Coating Layer DPP4-inhibitor (free 0.1 to 70%/0.2 to 140 1 to 50%/2 to 100 mg base or HCl salt) mg Coating polymer, and 1 to 70%/2 to 140 mg 1 to 50%/2 to 100 mg optional plasticizer and glidants Third Outer Protective Coating Layer Coating polymer, and 0.5 to 50%/1 to 100 1 to 5%/2 to 10 mg optional plasticizer, mg glidants and color - The following working Example represents a preferred embodiment of the invention.
- A 500 g batch of 2.5 mg DPP4 coated tablets having the following composition were prepared as described below
-
Weight (mg) % by weight of a 200 mg placebo core tablet Tablet Core Lactose Monohydrate NF 99 mg (49.5%) Microcrystalline Cellulose NF 90 mg (45%) Croscarmellose Sodium NF 10 mg (5%) Magnesium Stearate NF 1 mg (0.5%) Total 200 mg (100.0%) Inner Seal Coating Layer 4 mg (2%) Opadry ® HP which contains the following ingredients Polyvinyl Alcohol 40% PEG 20% Talc 15% Titanium dioxide 25% Middle Layer DPP4-inhibitor, Saxaglipitin 2.5 mg (1.25%) Opadry ® HP 20 mg (10%) Outer Protective Layer Opadry ® HP 4 mg (2%) - The 500 g of tablet cores were prepared as follows.
- Lactose monohydrate, croscarmellose sodium, and microcrystalline cellulose were blended in a planetary mixer. The blend was then lubricated by blending with pre-screened magnesium stearate using a Turbula mixer. The lubricated blend was compressed using a single station press or using a rotary press into 200 mg placebo tablets.
- The inner seal coating suspension was prepared as follows.
- 0.1 N HCl (about 226.7 g) in a metal container was continuously stirred with a lightening mixer. 40 g Opadry® HP powder was quickly added into the vortex. After the powder addition was completed, mixing was continued at a low speed until a uniform mixture was visually evident. pH of the resulting suspension was measured and pH was adjusted to 2 using concentrated HCl or NaOH.
- A Glatt coater was set up according to the following parameters
-
-
Pump rate 3.5-5 ml/min Pan speed 20 rpm Air pressure 1.5 bar Inlet air temperature 50° C. Exhaust air temperature about 38° C. Air flow 80 m3/hour Gun to bed distance 6.5 inch Nozzle size 0.8 mm - The tablet cores were preheated in a coating pan for about 10 to 15 minutes. 30 heated tablets were weighed. Drying of the tablets was continued until the moisture was driven out of the tablet and tablet weight became constant. The final weight of 30 tablets was designed as A.
- The 30 tablets were coated with the inner seal coating suspension as prepared above employing the Glatt coater.
- The 30 tablets were weighed every 10 minutes (and the weight recorded) until the tablet weight reached the targeted weight (Equation 1). The coated tablets were dried by heating until the tablet weight became constant. The final weight of the so- coated tablets was designated as B.
-
Targeted weight=A×1.02=B Equation 1: - The middle drug-containing coating layer suspension was prepared as follows.
- 12.5 g of the DPP4-inhibitor (free base) was added to 1000 ml of 0.1 N HCl in a metal container. The pH was measured and adjusted to 2. The HCl was continuously stirred and 100 g Opadry® HP was quickly added into the vortex. The mixture was then stirred at low speed until a uniform mixture was visually evident. The pH of the suspension was maintained at 2 using either concentrated HCl or 1N HCl as necessary.
- The seal coated tablet cores prepared above were coated with the coating suspension containing the DPP4-inhibitor prepared above employing the Glatt coater. The 30 seal coated tablets were weighed, initially every 30 minutes, then every 15 minutes and the weight recorded until the targeted weight was reached (Equation 2). The so-coated tablets were dried by heating until the tablet weight became constant. The final weight of 30 tablets was designated as C.
-
Targeted weight=B+30×(2.925 (equivalent to 2.5 mg free base)+20 mg)=B+687.75 mg=C Equation 2: - The amount of drug coated onto the tablets was determined using HPLC, fiber optic probe, or NIR or other suitable means. Coating was stopped when the targeted amount of drug was deposited.
- The so-coated tablets were then coated with a suspension of Opadry® HP as used in forming the inner seal coating. The 30 tablets were weighed every 10 minutes and the weight recorded until tablet weight reached the targeted weight (Equation 3). The tablets were dried by heating until the tablet weight became constant. The final weight of 30 tablets was designed as D.
-
Targeted weight=C+30×4 mg=C+120 mg=D Equation 3: - The so-coated tablets were transferred to a suitable container.
- The tablets of the invention so-prepared had superior stability to conventional tablet formulations (wherein the drug was in the core) and capsule formulations.
- The above 2.5 mg potency coated tablets of the invention were stored at various storage conditions up to and including 41 weeks and stability data related to presence of the degradant cyclic amidine (mainly cis-cyclic amidine (Cis-CA)) were collected. As shown in Table 1 set out below, no cis-CA was detected at 25° C./60% RH storage condition. The cis-CA levels were 0.22% and 0.32% at 30° C./60% RH and 40° C./75% RH storage conditions, respectively. These levels are significantly lower than those observed in the 5 mg and 20 mg potency capsule formulations shown in Table 2.
-
TABLE 1 Twenty-six weeks stability data on 2.5 mg potency tablets coated with Opadry ® HP, free base as starting material, and three coating layers. For stability evaluation, tablets were packaged in HDPE bottles. 4 wks for all closed 8 wks for all closed conditions conditions 2 wks for all closed 1 wk for two open 5 wks for two open conditions conditions conditions Amide Cis- Trans- Amide Cis- Trans- Amide Cis- Trans- Storage Condition % CA % CA % % CA % CA % % CA % CA % 5° C.-closed 0 0 0 0 0 0 0 0 0 25° C./60% RH-closed 0 0 0 0 0 0 0 0 0 30° C./60% RH-closed 0 0 0 0 0 0 0 0 0 40° C./75% RH-closed 0 0 0 0 0.05 0 0 0.09 0 50° C.-closed 0 0.17 0 0 0.33 0.15 0 0.52 0.12 30° C./60% RH-open NA NA NA 0 0 0 0 0.20 0.06 40° C./75% RH-open NA NA NA 0 0.68 0.15 0 3.22 0.42 12 wks for all closed 26 wks for all closed 41 wks for all closed conditions conditions conditions Amide Cis- Trans- Amide Cis- Trans- Amide Cis- Trans- Storage Condition % CA % CA % % CA % CA % % CA % CA % 5° C.-closed 0 0 0 0 0 0 0 0 0 25° C./60% RH-closed 0 0 0 0 0 0 0.03 0 0 30° C./60% RH-closed 0 0 0 0 0.22 0 0.03 0.17 0 40° C./75% RH-closed 0 0.20 0.05 0 0.32 0 0.03 0.90 0 50° C.-closed 0 0.75 0.15 0 1.00 0 0 1.62 0 30° C./60% RH-open NA NA NA NA NA NA NA NA NA 40° C./75% RH-open NA NA NA NA NA NA NA NA NA NA denotes “data not available” -
TABLE 2 Stability data for capsule formulations (benzoate salt of DPP4 4.8%, Anhydrous lactose 50.2%, lactose hydrous 40%, croscarmellose sodium 2%, and sodium stearyl fumarate 3%, fill weights for 5 mg and 20 mg capsules are 150 mg and 350 mg, respectively.) 5 mg capsule 20 mg capsule 2 wks 4 wks 13 wks 26 wks 2 wks 4 wks 13 wks 26 wks Conditions Cis-CA % Cis-CA % Cis-CA % Cis-CA % Cis-CA % Cis-CA % Cis-CA % Cis-CA % 25° C./60% RH-closed 0.11 0.13 0.20 0.31 0.08 0.05 0.14 0.26 40° C./75% RH-closed 0.23 0.35 0.61 0.95 0.22 0.26 0.46 0.62 50° C.-closed NA 0.73 1.72 NA NA 0.43 1.19 NA
Claims (20)
1. A coated tablet comprising
a) a tablet core;
b) an inner seal coating layer coated on the tablet core, wherein the inner seal coating layer comprises at least one coating layer polymer;
c) a second coating layer coated on the inner seal coating layer, wherein the second coating layer comprises saxagliptin
or a pharmaceutically acceptable salt thereof and at least one coating layer polymer, and
d) optionally a third outer protective coating layer coated on the second coating layer, wherein the third outer protective coating layer comprises at least one coating layer polymer.
2. The coated tablet as defined in claim 1 , wherein the saxagliptin is present as a hydrochloride salt.
3. The coated tablet as defined in claim 1 , wherein the inner seal coating layer comprises at least one coating layer polymer selected from the group consisting of hydroxypropyl methylcellulose, polyvinyl alcohol, ethyl cellulose, methacrylic polymers and hydroxypropyl cellulose.
4. The coated tablet as defined in claim 3 , wherein the at least one coating layer polymer is polyvinyl alcohol.
5. The coated tablet as defined in claim 1 , wherein the second coating layer coated on the inner seal coating layer comprises saxagliptin
or a pharmaceutically acceptable salt thereof and at least one coating layer polymer selected from the group consisting of hydroxypropyl methylcellulose, polyvinyl alcohol, ethyl cellulose, methacrylic polymers and hydroxypropyl cellulose.
6. The coated tablet as defined in claim 5 , wherein the at least one coating layer polymer is polyvinyl alcohol.
7. The coated tablet as defined in claim 1 , wherein the inner seal coating layer further comprises polyethylene glycol.
8. The coated tablet as defined in claim 1 , wherein the second coating layer further comprises polyethylene glycol.
9. A coated tablet comprising
a) a tablet core;
b) an inner seal coating layer coated on the tablet core, wherein the inner seal coating layer comprises at least one coating layer polymer;
c) a second coating layer coated on the inner seal coating layer, wherein the second coating layer comprises saxagliptin
or a pharmaceutically acceptable salt thereof and at least one coating layer polymer, and
d) a third outer protective coating layer coated on the second coating layer, wherein the third outer protective coating layer comprises at least one coating layer polymer.
10. The coated tablet as defined in claim 9 , wherein the saxagliptin is present as a hydrochloride salt.
11. The coated tablet as defined in claim 9 , wherein the third outer protective coating layer coated on the second coating layer comprises at least one coating layer polymer selected from the group consisting of hydroxypropyl methylcellulose, polyvinyl alcohol, ethyl cellulose, methacrylic polymers and hydroxypropyl cellulose;wherein the at least one coating polymer.
12. The coated tablet as defined in claim 11 , wherein the at least one coating layer polymer is polyvinyl alcohol.
13. The coated tablet as defined in claim 9 , wherein the third outer protective coating layer further comprises polyethylene glycol.
14. A combination formulation comprising
a) a drug tablet;
b) an inner seal coating layer coated on the drug tablet, wherein the inner seal coating layer comprises at least one coating layer polymer;
c) a second coating layer coated on the inner seal coating layer, wherein the second coating layer comprises saxagliptin
or a pharmaceutically acceptable salt thereof and at least one coating layer polymer, and
d) a third outer protective coating layer coated on the second coating layer, wherein the third outer protective coating layer comprises at least one coating layer polymer;
wherein the drug tablet comprises a drug other than saxagliptin or a pharmaceutically acceptable salt thereof.
15. The combination formulation as defined in claim 14 , wherein the saxagliptin is present as a hydrochloride salt.
16. The combination formulation as defined in claim 14 , wherein the inner seal coating layer comprises at least one coating layer polymer selected from the group consisting of hydroxypropyl methylcellulose, polyvinyl alcohol, ethyl cellulose, methacrylic polymers and hydroxypropyl cellulose.
17. The combination formulation as defined in claim 16 , wherein the at least one coating layer polymer is polyvinyl alcohol.
18. The combination formulation as defined in claim 14 , wherein the second coating layer coated on the inner seal coating layer comprises saxagliptin
or a pharmaceutically acceptable salt thereof and at least one coating layer polymer selected from the group consisting of hydroxypropyl methylcellulose, polyvinyl alcohol, ethyl cellulose, methacrylic polymers and hydroxypropyl cellulose.
19. The combination formulation as defined in claim 14 , wherein the third outer protective coating layer coated on the second coating layer comprises at least one coating layer polymer selected from the group consisting of hydroxypropyl methylcellulose, polyvinyl alcohol, ethyl cellulose, methacrylic polymers and hydroxypropyl cellulose;wherein the at least one coating polymer.
20. The combination formulation as defined in claim 19 , wherein the at least one coating layer polymer is polyvinyl alcohol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/284,840 US20140255486A1 (en) | 2004-05-28 | 2014-05-22 | Coated Tablet Formulation and Method |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57531904P | 2004-05-28 | 2004-05-28 | |
US11/137,068 US7951400B2 (en) | 2004-05-28 | 2005-05-25 | Coated tablet formulation and method |
US13/094,379 US8628799B2 (en) | 2004-05-28 | 2011-04-26 | Coated tablet formulation and method |
US14/150,331 US9339472B2 (en) | 2004-05-28 | 2014-01-08 | Coated tablet formulation and method |
US14/284,840 US20140255486A1 (en) | 2004-05-28 | 2014-05-22 | Coated Tablet Formulation and Method |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/150,331 Continuation US9339472B2 (en) | 2004-05-28 | 2014-01-08 | Coated tablet formulation and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140255486A1 true US20140255486A1 (en) | 2014-09-11 |
Family
ID=34971747
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/137,068 Active 2028-11-30 US7951400B2 (en) | 2004-05-28 | 2005-05-25 | Coated tablet formulation and method |
US13/094,379 Active 2025-07-13 US8628799B2 (en) | 2004-05-28 | 2011-04-26 | Coated tablet formulation and method |
US14/150,331 Active 2025-10-14 US9339472B2 (en) | 2004-05-28 | 2014-01-08 | Coated tablet formulation and method |
US14/284,840 Abandoned US20140255486A1 (en) | 2004-05-28 | 2014-05-22 | Coated Tablet Formulation and Method |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/137,068 Active 2028-11-30 US7951400B2 (en) | 2004-05-28 | 2005-05-25 | Coated tablet formulation and method |
US13/094,379 Active 2025-07-13 US8628799B2 (en) | 2004-05-28 | 2011-04-26 | Coated tablet formulation and method |
US14/150,331 Active 2025-10-14 US9339472B2 (en) | 2004-05-28 | 2014-01-08 | Coated tablet formulation and method |
Country Status (33)
Country | Link |
---|---|
US (4) | US7951400B2 (en) |
EP (3) | EP2298288B2 (en) |
JP (1) | JP4901727B2 (en) |
KR (2) | KR101290925B1 (en) |
CN (2) | CN1988891B (en) |
AR (2) | AR049062A1 (en) |
AU (1) | AU2005249467B2 (en) |
BR (1) | BRPI0510419B8 (en) |
CA (1) | CA2568391C (en) |
CY (2) | CY1117813T1 (en) |
DK (2) | DK2298288T4 (en) |
ES (3) | ES2754573T3 (en) |
GE (1) | GEP20094639B (en) |
HK (2) | HK1155399A1 (en) |
HR (2) | HRP20160880T4 (en) |
HU (2) | HUE029446T2 (en) |
IL (2) | IL179454A (en) |
LT (1) | LT2298288T (en) |
ME (2) | ME02643B (en) |
MX (1) | MXPA06013711A (en) |
MY (1) | MY147639A (en) |
NO (1) | NO343907B1 (en) |
NZ (1) | NZ551591A (en) |
PE (1) | PE20060425A1 (en) |
PL (2) | PL1753406T5 (en) |
PT (2) | PT1753406E (en) |
RS (2) | RS55174B2 (en) |
RU (1) | RU2372894C2 (en) |
SI (3) | SI1753406T2 (en) |
TW (2) | TWI354569B (en) |
UA (1) | UA88168C2 (en) |
WO (1) | WO2005117841A1 (en) |
ZA (1) | ZA200609541B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9339472B2 (en) | 2004-05-28 | 2016-05-17 | Astrazeneca Ab | Coated tablet formulation and method |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0487425A (en) * | 1990-07-31 | 1992-03-19 | Fujitsu Ltd | Circuit switching device |
PT1368349E (en) * | 2001-02-24 | 2007-04-30 | Boehringer Ingelheim Pharma | Xanthine derivative, production and use thereof as a medicament |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
KR101130433B1 (en) * | 2004-02-05 | 2012-03-27 | 교린 세이야꾸 가부시키 가이샤 | Bicycloester derivative |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
DE102005035891A1 (en) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
GB0526291D0 (en) * | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
JP2009526047A (en) * | 2006-02-09 | 2009-07-16 | テバ ファーマシューティカル インダストリーズ リミティド | Stable pharmaceutical formulation of Montelukast sodium |
CN101395131B (en) * | 2006-03-08 | 2012-11-14 | 杏林制药株式会社 | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
MX2008014024A (en) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Polymorphs. |
EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
JPWO2008114857A1 (en) * | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | Process for producing aminoacetylpyrrolidinecarbonitrile derivative |
PE20090185A1 (en) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR |
PE20090696A1 (en) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM |
WO2009002823A2 (en) * | 2007-06-22 | 2008-12-31 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
DE602008005462D1 (en) * | 2007-06-22 | 2011-04-21 | Bristol Myers Squibb Co | TABLETTED ATAZANA-CONTAINING COMPOSITIONS |
DK2170292T3 (en) * | 2007-06-22 | 2014-04-07 | Bristol Myers Squibb Holdings Ireland | Tablet-containing Atazanavir Compositions |
US20100183716A1 (en) * | 2007-06-22 | 2010-07-22 | Bristo-Meyers Squibb Company | Tableted compositions containing atazanavir |
CN101772304B (en) * | 2007-07-31 | 2014-07-09 | 卡吉尔公司 | Direct compressible dextrose |
ES2692437T3 (en) | 2007-08-13 | 2018-12-03 | Abuse Deterrent Pharmaceutical Llc | Abuse-resistant drugs, method of use and method of preparation |
CL2008002427A1 (en) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus. |
US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
PE20091730A1 (en) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
IT1393244B1 (en) * | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | SYSTEM FOR THE RELEASE TO COLON OF SUSCEPTIBLE DRUGS OF ENZYMATIC DEGRADATION AND / OR SHORTLY ABSORBED IN THE GASTROINTESTINAL TRACT |
UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
CA2732984A1 (en) * | 2008-08-07 | 2010-02-11 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
AU2009282376A1 (en) * | 2008-08-12 | 2010-02-18 | Inspirion Delivery Technologies, Llc | Pharmaceutical compositions configured to deter dosage form splitting |
CN102186474A (en) * | 2008-08-14 | 2011-09-14 | 杏林制药株式会社 | Uchida hiroshi [jp]; fukuda mamoru [jp]; aritomi seigo |
WO2010018217A2 (en) | 2008-08-15 | 2010-02-18 | Boehringer Ingelheim International Gmbh | Organic compounds for wound healing |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
DE102008059206A1 (en) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic |
CN107011345A (en) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | The salt form of organic compound |
AR074990A1 (en) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY |
TWI466672B (en) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | Treatment for diabetes in paediatric patients |
EA029759B1 (en) | 2009-02-13 | 2018-05-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Antidiabetic medications comprising dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetic agents |
AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
MX2011009852A (en) | 2009-03-27 | 2011-09-29 | Bristol Myers Squibb Co | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors. |
RU2011142829A (en) | 2009-03-27 | 2013-05-10 | Киорин Фармасьютикал Ко., Лтд. | MATRIX TYPE PRODUCT WITH PROLONGED RELEASE CONTAINING A BASIC ADDITIVE |
CA2757934C (en) * | 2009-04-09 | 2017-12-19 | Sandoz Ag | Crystal forms of saxagliptin |
PL2498758T3 (en) | 2009-11-13 | 2019-02-28 | Astrazeneca Ab | Bilayer tablet formulations |
MX2012005365A (en) | 2009-11-13 | 2012-05-29 | Bristol Myers Squibb Co | Immediate release tablet formulations. |
EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
CN102210693B (en) * | 2010-04-10 | 2013-10-09 | 山东新华制药股份有限公司 | Method for preparing aspirin and dipyridamole multilayer tablets |
AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
WO2011140328A1 (en) | 2010-05-05 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof |
BR112012032579B1 (en) | 2010-06-24 | 2021-05-11 | Boehringer Ingelheim International Gmbh | use of linagliptin and pharmaceutical composition comprising linagliptin and long-acting basal insulin |
EP2601175A1 (en) | 2010-08-06 | 2013-06-12 | Sandoz AG | A novel crystalline compound comprising saxagliptin and phosphoric acid |
EP2601176A1 (en) | 2010-08-06 | 2013-06-12 | Sandoz AG | Novel salts of saxagrliptin with organic di-acids |
EP2611442B1 (en) | 2010-09-03 | 2018-07-04 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
EP2608788A1 (en) | 2010-10-04 | 2013-07-03 | Assia Chemical Industries Ltd. | Polymorphs of saxagliptin hydrochloride and processes for preparing them |
SG190029A1 (en) | 2010-11-08 | 2013-06-28 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
CN102086172A (en) * | 2011-01-13 | 2011-06-08 | 廖国超 | Medicinal salts of saxagliptin and preparation methods of medicinal salts |
WO2012106303A1 (en) | 2011-02-01 | 2012-08-09 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
HUE043540T2 (en) | 2011-07-15 | 2019-08-28 | Boehringer Ingelheim Int | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
KR20140057604A (en) | 2011-08-12 | 2014-05-13 | 베링거잉겔하임베트메디카게엠베하 | Funny current(if) inhibitors for use in a method of treating and preventing heart failure in feline |
EA201490556A1 (en) | 2011-09-07 | 2014-08-29 | Сановел Илач Санайи Ве Тиджарет Аноним Ширкети | COMPOSITIONS OF DPP-4 INHIBITOR |
US9446000B2 (en) | 2011-09-08 | 2016-09-20 | Masdar Institute Of Science And Technology | Cellulosic gel material as a pharmaceutical excipient |
PL2578208T3 (en) | 2011-10-06 | 2014-10-31 | Sanovel Ilac Sanayi Ve Ticaret As | DPP-IV inhibitor solid dosage formulations |
US20130189358A1 (en) | 2012-01-10 | 2013-07-25 | Roey Solomonovich | Saxagliptin pharmaceutical formulations |
WO2013130785A2 (en) | 2012-03-01 | 2013-09-06 | Bristol-Myers Squibb Company | Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
SG11201406363VA (en) | 2012-05-07 | 2014-11-27 | Bayer Pharma AG | Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2013179307A2 (en) * | 2012-05-29 | 2013-12-05 | Mylan Laboratories Limited | Stabilized pharmaceutical compositions of saxagliptin |
WO2014030051A1 (en) | 2012-08-23 | 2014-02-27 | Aurobindo Pharma Limited | Stable pharmaceutical compositions comprising saxagliptin |
JP6283316B2 (en) * | 2012-10-26 | 2018-02-21 | 株式会社三和化学研究所 | Anagliptin-containing solid preparation |
US20150250734A1 (en) * | 2012-12-21 | 2015-09-10 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
WO2014096983A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
WO2014146093A2 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
WO2014193528A1 (en) * | 2013-04-29 | 2014-12-04 | Anovel Pharmaceuticals, Llc | Amorphous dosage forms and methods |
CN103316056B (en) * | 2013-06-24 | 2015-07-08 | 江苏鹏鹞药业有限公司 | Radix isatidis coating dispersible tablet and preparation method thereof |
WO2015071889A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
WO2015071887A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of saxagliptin |
AU2015209674B2 (en) * | 2014-01-21 | 2018-11-08 | Bpsi Holdings, Llc | Immediate release film coatings containing medium chain glycerides and substrates coated therewith |
ES2950384T3 (en) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Medical use of a DPP-4 inhibitor |
KR102560954B1 (en) * | 2014-06-25 | 2023-07-31 | 이에이 파마 가부시키가이샤 | Solid preparation, and method for preventing or reducing discoloration thereof |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
CN105520913B (en) * | 2014-09-28 | 2020-06-23 | 石药集团中奇制药技术(石家庄)有限公司 | Pellet containing saxagliptin, application and preparation method thereof |
CN105497023B (en) * | 2014-10-15 | 2021-05-25 | 北京福元医药股份有限公司 | Saxagliptin pharmaceutical preparation |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
CN104557943B (en) * | 2014-12-23 | 2017-05-03 | 扬子江药业集团四川海蓉药业有限公司 | Preparation method of vildagliptin impurities |
CN105796503B (en) * | 2014-12-30 | 2019-05-07 | 深圳翰宇药业股份有限公司 | A kind of saxagliptin pellet and its preparation |
CN104672243B (en) * | 2015-02-10 | 2017-09-22 | 华润赛科药业有限责任公司 | The preparation method of vildagliptin degradation impurity |
PL3277278T3 (en) | 2015-04-02 | 2020-07-27 | Theravance Biopharma R&D Ip, Llc | Combination dosage form of a mu opioid receptor antagonist and an opioid agent |
CN106176661B (en) * | 2015-04-29 | 2019-02-01 | 四川科伦药物研究院有限公司 | A kind of saxagliptin or the capsule of its salt and preparation method thereof |
TWI804919B (en) * | 2015-06-30 | 2023-06-11 | 美商建南德克公司 | Immediate-release tablets containing a drug and processes for forming the tablets |
CN106924207A (en) * | 2015-12-31 | 2017-07-07 | 深圳翰宇药业股份有限公司 | A kind of vildagliptin tablet and preparation method thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
BR112018072401A2 (en) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinations of linagliptin and metformin |
CN111032019B (en) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | Cholestyramine granules, oral cholestyramine preparation and application thereof |
CN108822820B (en) * | 2018-05-22 | 2020-11-03 | 东莞理工学院 | Isolated hydrate kinetic inhibition capsule and preparation method and application thereof |
EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3100691A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
WO2020098904A1 (en) | 2018-11-12 | 2020-05-22 | Pharmaceutical Oriented Services Ltd | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
CN109999006A (en) * | 2019-04-28 | 2019-07-12 | 江苏豪森药业集团有限公司 | Saxagliptin coating tablet and preparation method thereof |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
JP2023504647A (en) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP2023504645A (en) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
CN114761080A (en) | 2019-12-04 | 2022-07-15 | 阿尔比里奥公司 | Benzothia (di) azepin compounds and their use as bile acid modulators |
EP4069247A1 (en) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
JP2022003016A (en) | 2020-06-23 | 2022-01-11 | 沢井製薬株式会社 | Saxagliptin-containing preparation and its manufacturing method |
JP2023537285A (en) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
AU2021390172A1 (en) | 2020-12-04 | 2023-06-22 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20220165346A (en) | 2021-06-08 | 2022-12-15 | 동아에스티 주식회사 | Formulation comprising evogliptin with improved stability |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3696188A (en) * | 1971-06-16 | 1972-10-03 | Schering Corp | Laminated tablets |
DE3403329A1 (en) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | PHARMACEUTICAL PRODUCT IN THE FORM OF PELLETS WITH CONTINUOUS, DELAYED DELIVERY OF ACTIVE SUBSTANCES |
JPS6186211A (en) | 1984-10-04 | 1986-05-01 | 日本碍子株式会社 | Ceramics composite structure and manufacture thereof |
FR2623810B2 (en) | 1987-02-17 | 1992-01-24 | Sanofi Sa | ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
US5158777A (en) | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
CA2068402C (en) | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
US5428048A (en) | 1993-11-08 | 1995-06-27 | American Home Products Corporation | Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
TW522014B (en) | 1997-02-07 | 2003-03-01 | Sepracor Inc | Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine |
GB9715896D0 (en) | 1997-07-28 | 1997-10-01 | Sca Packaging Ltd | Containers |
US6087383A (en) | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
AU765128B2 (en) | 1999-03-22 | 2003-09-11 | Bristol-Myers Squibb Company | Fused pyridopyridazine inhibitors of cGMP phosphodiesterase |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
TWI271192B (en) | 1999-11-11 | 2007-01-21 | Kyorin Pharmaceutical Co Ltd | Solid formulation for oral administration |
US6569456B2 (en) * | 2000-01-13 | 2003-05-27 | Osmotica Corp. | Osmotic device containing diltiazem and an ACE inhibitor or diuretic |
ES2436610T3 (en) | 2000-01-21 | 2014-01-03 | Novartis Ag | Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
US6254888B1 (en) | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
IL145106A0 (en) | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
US6670344B2 (en) | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
US6670334B2 (en) * | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
NZ528957A (en) | 2001-04-18 | 2005-05-27 | Nostrum Pharmaceuticals Inc | A novel coating for a sustained release pharmaceutical composition |
US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
AU2003201071A1 (en) | 2002-01-15 | 2003-07-30 | Ranbaxy Laboratories Limited | Stable pharmaceutical compositions comprising ace inhibitor(s) |
KR100456833B1 (en) | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | Cored tablets containing amoxycillin and clavulanate |
US7670624B2 (en) | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
TW200534879A (en) | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US20050256314A1 (en) | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
US20050288343A1 (en) | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
-
2005
- 2005-05-23 TW TW094116772A patent/TWI354569B/en not_active IP Right Cessation
- 2005-05-23 TW TW100134799A patent/TWI415635B/en not_active IP Right Cessation
- 2005-05-25 US US11/137,068 patent/US7951400B2/en active Active
- 2005-05-26 ME MEP-2016-213A patent/ME02643B/en unknown
- 2005-05-26 PT PT05756474T patent/PT1753406E/en unknown
- 2005-05-26 ES ES16166031T patent/ES2754573T3/en active Active
- 2005-05-26 CN CN2005800245879A patent/CN1988891B/en active Active
- 2005-05-26 KR KR1020067024818A patent/KR101290925B1/en active IP Right Grant
- 2005-05-26 EP EP10179007.9A patent/EP2298288B2/en active Active
- 2005-05-26 RU RU2006146971/15A patent/RU2372894C2/en active
- 2005-05-26 RS RS20160797A patent/RS55174B2/en unknown
- 2005-05-26 ES ES05756474T patent/ES2582646T5/en active Active
- 2005-05-26 KR KR1020127014475A patent/KR20120064141A/en not_active Application Discontinuation
- 2005-05-26 RS RS20160563 patent/RS54929B2/en unknown
- 2005-05-26 ME MEP-2016-145A patent/ME02516B/en unknown
- 2005-05-26 HU HUE10179007A patent/HUE029446T2/en unknown
- 2005-05-26 EP EP16166031.1A patent/EP3078369B1/en active Active
- 2005-05-26 PT PT101790079T patent/PT2298288T/en unknown
- 2005-05-26 UA UAA200613939A patent/UA88168C2/en unknown
- 2005-05-26 PL PL05756474T patent/PL1753406T5/en unknown
- 2005-05-26 NZ NZ551591A patent/NZ551591A/en unknown
- 2005-05-26 SI SI200532082T patent/SI1753406T2/en unknown
- 2005-05-26 GE GEAP20059797A patent/GEP20094639B/en unknown
- 2005-05-26 MX MXPA06013711A patent/MXPA06013711A/en active IP Right Grant
- 2005-05-26 SI SI200532097T patent/SI2298288T2/en unknown
- 2005-05-26 AU AU2005249467A patent/AU2005249467B2/en active Active
- 2005-05-26 WO PCT/US2005/018692 patent/WO2005117841A1/en active Application Filing
- 2005-05-26 JP JP2007515382A patent/JP4901727B2/en active Active
- 2005-05-26 EP EP05756474.2A patent/EP1753406B2/en active Active
- 2005-05-26 CN CN201210377942.2A patent/CN102895208B/en active Active
- 2005-05-26 DK DK10179007.9T patent/DK2298288T4/en active
- 2005-05-26 HU HUE05756474A patent/HUE029039T2/en unknown
- 2005-05-26 ES ES10179007T patent/ES2593582T5/en active Active
- 2005-05-26 PL PL10179007T patent/PL2298288T5/en unknown
- 2005-05-26 DK DK05756474T patent/DK1753406T4/en active
- 2005-05-26 CA CA2568391A patent/CA2568391C/en not_active Expired - Fee Related
- 2005-05-26 MY MYPI20052400A patent/MY147639A/en unknown
- 2005-05-26 BR BRPI0510419A patent/BRPI0510419B8/en active IP Right Grant
- 2005-05-26 LT LTEP10179007.9T patent/LT2298288T/en unknown
- 2005-05-26 SI SI200532082A patent/SI1753406T1/en unknown
- 2005-05-27 AR ARP050102188A patent/AR049062A1/en not_active Application Discontinuation
- 2005-05-30 PE PE2005000601A patent/PE20060425A1/en active IP Right Grant
-
2006
- 2006-11-16 ZA ZA2006/09541A patent/ZA200609541B/en unknown
- 2006-11-21 IL IL179454A patent/IL179454A/en active IP Right Grant
- 2006-12-15 NO NO20065870A patent/NO343907B1/en unknown
-
2007
- 2007-03-06 HK HK11109873.0A patent/HK1155399A1/en active IP Right Maintenance
- 2007-03-06 HK HK07102473.5A patent/HK1094951A1/en active IP Right Maintenance
-
2011
- 2011-04-26 US US13/094,379 patent/US8628799B2/en active Active
-
2012
- 2012-02-14 IL IL218117A patent/IL218117A/en active IP Right Grant
-
2014
- 2014-01-08 US US14/150,331 patent/US9339472B2/en active Active
- 2014-05-22 US US14/284,840 patent/US20140255486A1/en not_active Abandoned
-
2015
- 2015-02-24 AR ARP150100554A patent/AR099567A2/en unknown
-
2016
- 2016-07-15 HR HRP20160880TT patent/HRP20160880T4/en unknown
- 2016-07-19 CY CY20161100703T patent/CY1117813T1/en unknown
- 2016-09-21 HR HRP20161210TT patent/HRP20161210T4/en unknown
- 2016-09-22 CY CY20161100945T patent/CY1118162T1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9339472B2 (en) | 2004-05-28 | 2016-05-17 | Astrazeneca Ab | Coated tablet formulation and method |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9339472B2 (en) | Coated tablet formulation and method | |
US20050214373A1 (en) | Coated tablet formulation and method | |
JP2021525722A (en) | Combinations, compositions, formulations of pharmaceuticals containing glucokinase activators and α-glucosidase inhibitors, and methods and uses thereof. | |
US20150250734A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
WO2014096983A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |